SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-20-002907
Filing Date
2020-11-20
Accepted
2020-11-20 13:13:50
Documents
7
Period of Report
2020-11-19

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 10168
2 EX-99.1 nymox_ex991.htm EX-99.1 6034
3 EX-99.2 nymox_ex992.htm EX-99.2 145631
4 EX-99.3 nymox_ex993.htm EX-99.3 1755
5 nymox_ex992img1.jpg GRAPHIC 631
6 nymox_ex993img1.jpg GRAPHIC 146980
7 nymox_ex993img2.jpg GRAPHIC 108179
  Complete submission text file 0001640334-20-002907.txt   517260
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 201331760
SIC: 2835 In Vitro & In Vivo Diagnostic Substances